GLAXO Stock View

GlaxoSmithKline Pharmaceuticals Ltd

GLAXO Stock View

(NSE)

Trade

₹ 1,695.65

-4.45 | -0.26

Market Cap ₹( Cr.)
287,253.30

Proj. P/E (x)
44.34

Proj. P/BV (x)
15.08

Proj. ROE (%)
35.62

Proj EV / EBITDA (x)
--

Proj. Revenue ( Cr.)
34,088.00

HOLD

Last Updated On.
03-Dec-2023

 

Copy Link

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data